Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. reports clinical-stage biopharmaceutical developments focused on targeted, non-systemic therapies for gastrointestinal diseases. Recurring news includes updates on latiglutenase, an oral biotherapeutic composed of gluten-specific recombinant proteases for celiac disease, as well as scientific publications, conference abstracts, and diagnostic research related to serologic and mucosal measures in celiac disease.
Company updates also cover investor conference participation, clinical development strategy, material agreements, shareholder voting matters, capital-structure disclosures, governance items, operating results, and clinical or regulatory disclosures tied to its GI disease pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.